Once-Daily Abacavir/Lamivudine/Zidovudine plus Tenofovir for the Treatment of HIV-1 Infection in Antiretroviral-NaïveSubjects: A 48-Week Pilot Study

REFERENCES

• Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA. 2001285: 1155–1163.
   Google Scholar
• Ait-Khaled M, Lanier R, Richards N, et al. Zidovudine ap-pears to prevent selection of K65R and L74V mutations normally selected by abacavir mono- or combination therapies not containing zidovudine [Abstract 129]. Antivir Ther. 2002;7:S107.
   Web of Science ®Google Scholar
• Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther. 1999; 4:87–94.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, DeJesus E, Cahn P, et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naIve HIV-infected adults. J Acquir Immune Defic Syndr. 2005;38:417–425.
   PubMed Web of Science ®Google Scholar
• DeJesus E, McCarty D, Farthing CF, et al. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis. 2004;39:411–418.
   PubMed Web of Science ®Google Scholar
• Ruane PJ, Richmond GJ, DeJesus et al. Pharmacody-namic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with hu-man immunodeficiency virus. Pharmacotherapy. 2004;24:307–312.
   PubMed Web of Science ®Google Scholar
• Miller MD, Anton KE, Mulato AS, et al. Human immunodefi-ciency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capa-bility in vitro. J Infect Dis. 1999 179:92–100.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Rodriguez AE, Weinberg W, et al. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (ER)) + ABC + 3TC: E5530009 unplanned interim analysis. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Che-motherapy; September 14–17, 2003; San Diego, CA. Ab-stract H–1722a.
   Google Scholar
• Farthing C, Khanlou H, Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine, and tenofovir in treatment-naïve HIV-infected patients. Antivir Ther. 2003;8\(suppl 1): Abstract 43.
   Google Scholar
• Elion R, Cohen C, DeJesus E, et al. C0L40263: resistance and efficacy of once-daily Trizivir and tenofovir DF in antiretroviral naïve subjects. In: 11th Conference on Retroviruses & Opportunistic Infections; February 8–11, 2004; San Francisco, CA. Abstract M–138.
   Google Scholar
• Regulatory Compliance Center. Division of AIDS (DAIDS) Table of Grading Severity of Adult Adverse Experiences. Betheseda, MD: National Institute of Allergy and Infectious Diseases; August 1992.
   Google Scholar
• Paulsen DM, Hill BJ, Hernandez J, McComsey G, Ross LL. Quantification of mitochondria! DNA in human cells using real-time PCR with fluorogenic reporters. In: Abstracts of the XIV International Conference on AIDS; July 2002; Barcelona. Abstract B4509.
   Google Scholar
• DeJesus E, Elion R, Cohen C, et al. Week 24 analysis of once-daily (QD) Trizivir (TZV) and tenofovir DF (TDF) in antiretroviral-naive subjects (C0L40263). In: Program and abstracts of the 44th Interscience Conference on Antimi-crobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC. Abstract H–456.
   Google Scholar
• Khanlou H, Yeh V, Guyer B, Farthing C. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naïve HIV-infected patients. AIDS Patient Care STDS. 2005;19(3):135–140.
   PubMed Web of Science ®Google Scholar
• Landman R, Descamps D, Peytavin G, et al. Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial therapy of HIV-1 infection: TONUS study. HIV Clin Trials. 2005;6:291–305.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Rodriguez AE, Weinberg WG, et al. Early viro-logic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naïve subjects. J Infect Dis. 2005;192:1921–1930.
   PubMed Web of Science ®Google Scholar
• Jemsek J, Hutcherson P, Harper E. Poor virologic re-sponses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. In: Program and abstracts of the 11th Confer-ence on Retroviruses and Opportunistic Infections. Febru-ary 8–11 2004; San Francisco, CA. Abstract 51
   Google Scholar
• Roge BT, Katzenstein TL, Obel N, et al. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir Ther. 2003,8:173–182.
   PubMed Web of Science ®Google Scholar
• Gerstoft J, Kirk O, Obel N, et al. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS. 2003,17: 2045–2052.
   PubMed Web of Science ®Google Scholar
• van Leeuwen R, Katlama C, Murphy RL, et al. A random-ized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS. 2003,17:987–999.
   PubMed Web of Science ®Google Scholar
• DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS. 2006;20:1391–1399.
   PubMed Web of Science ®Google Scholar
• Elion R, Ha B, DeJesus E, Cohen C, et al. Selection of HIV reverse transcriptase (RT) thymidine analogue mutations (TAMS) rather then K65R is the preferred route of resis-tance seen in patients with virologic failure (\/F) on once-daily (QD) Trizivir (TZV) and tenofovir (TDF). In: Program and abstracts of the 45th Interscience Conference on Anti-microbial Agents and Chemotherapy; December 16–19, 2005; Washington, DC. Abstract H–1068.
   Google Scholar
• Moyle G, Higgs C, Teague A, et al. An open-label, random-ized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. Antivir Ther. 2006;11:73–78.
   PubMed Web of Science ®Google Scholar
• Gulick R, Lalama C, Shikuma C, et al. Randomized intensi-fication of a triple nucleoside regimen with efavirenz or tenofovir in ACTG 5095. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 4–8, 2006; Denver, CO. Abstract 519.
   Google Scholar
• Greiger-Zanlungo M, Rubin, M, Blick, D, Garton, T. Qua-druple nucleoside reverse transcriptase inhibitor (NRTI) therapy with Trizivir® (TZV) and Viread® (TDF) in HAART-naive and -experienced HIV/AIDS patients. In: Program and abstracts of the 15th International AIDS Conference; July 11–16, 2004; Bangkok, Thailand. Abstract TuPeB4513.
   Google Scholar
• Dauer B, Carlebach A, Stuermer M, et al. Virologic re-sponse to tenofovir DF (TDF) plus Trizivir (TZV) therapy in heavily ART-experienced, HIV+ patients: 24 week results. In: Program and abstracts of the 45th Interscience Confer-ence on Antimicrobial Agents and Chemotherapy; Decem-ber 16–19, 2005; Washington, DC. Abstract H–520.
   Google Scholar
• Rodriguez A, Hill-Zababla C, Sloan L, et al. Patients experi-encing early virologic failure on a protease inhibitor- or nonnucleoside reverse transcriptase inhibitor-based initial regimen containing a thymidine analogue and lamivudine can be successfully treated with a quadruple-nucleoside regimen. J Acquir Immune Defic Syndr. 2006;41:127–129.
   PubMed Web of Science ®Google Scholar
• Latham V, Stebbing J, Mandalia S, et al. Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol. J Antimicrob Chemother. 2005;56:186–189.
   PubMed Web of Science ®Google Scholar
• Berenguer J, Perez-Elias MJ, Bellon JM, et al. Effective-ness and safety of abacavir, lamivudine, and zidovudine in antiretroviral-naive HIV-infected patients: results from a large multicenter observational cohort. J Acquir Immune Defic Syndr. 2006;41:154–159.
   PubMed Web of Science ®Google Scholar
• Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naïve HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004;35: 22–32.
   PubMed Web of Science ®Google Scholar
• Kumar P, Rodriguez-French A, Thompson M, et al. A pro-spective, 96-week study of the impact of Trizivir, Combivir/ nelfinavir, and lamivudine/stavudine/ nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive pa-tients: effect of sex and ethnicity. HIV Med. 2006;7:85–98.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, DeJesus E, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3 year randomized trial. JAMA. 2004;292:191–201.
   PubMed Web of Science ®Google Scholar
• Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir OF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Enql J Med. 2006;354: 251–260.
   PubMed Web of Science ®Google Scholar
• Shikuma C, Yang Y, Meyer WA, et al. Metabolic analyses within A5095: effect of efavirenz against an all nucleoside/ nucleotide background. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infec-tions; February 5–8, 2006; Denver, CO. Abstract N–166.
   Google Scholar
• Nolan D, Hammond E, Martin A, et al. Mitochondria! DNA depletion and morphologic changes in adipocytes associ-ated with nucleoside reverse transcriptase inhibitor therapy. AIDS. 2003;17:1329–1338.
   PubMed Web of Science ®Google Scholar
• Nolan D, Hammond E, James I, McKinnon E, Melia! S. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther. 2003;8:617–626.
   Google Scholar